Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Takeda: Clinical Trials & FDA Approval Profile

Takeda (Tokyo, JP / Cambridge, MA) sponsors 192 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 63 active protocols (43 recruiting now), 95 completed protocols, and 63 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.7%
Median Closed Enrollment vs National (145 pts)56 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Takeda
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)192
Active Pipeline (Recruiting Now)63 (43)
Completed vs Stopped Early95 / 34 (17.7%)
Median Closed Actual Enrollment56 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals63 (9 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Takeda
Hospital Research SiteLocationShared Protocols
Cleveland ClinicCleveland, OH23
Mayo Clinic RochesterRochester, MN20
UC San Diego Health and Moores Cancer CenterSan Diego, CA19

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Takeda
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06165341Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (FibPhase IIIRECRUITING
NCT05837897A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's DiseasePhase IIIRECRUITING
NCT06764615A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)Phase IIRECRUITING
NCT05677971Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an AbnormaPhase IIIRECRUITING
NCT06948318A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Takeda Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI